Diffuse Lung Disease
-
Phase 3 IMPALA-2 clinical trial shows inhaled molgramostim promising for autoimmune pulmonary alveolar proteinosis
An ongoing 96-week, open-label period of the trial is designed to shed light on the drug’s long-term safety and efficacy.
-
Early data suggest air pollution may initiate lung cancer
Researcher Peiyao Wang said early results show that fine particulate matter is causing permanent DNA damage, which could have implications for lung cancer screening.
-
Imaging panel discusses pace, direction of practical AI applications
Amit Gupta, MD, MRMD, CIIP, spoke about the growing application of AI imagery in early-stage lung cancer detection.
-
Study explores geographic disparities in tobacco dependence treatment among veterans with COPD
Study author Arianne K. Baldomero, MD, said that reducing geographic barriers will require multidisciplinary approaches and innovative, equitable health care solutions.
-
Closing the gap in pulmonary rehabilitation
If pulmonary rehabilitation in the United States is going to meet the scale of need in coming years, it must grow consistently, equitably, and sustainably.
-
Panelists address local approaches for clean air and climate action
Stephanie Lovinsky-Desir, MD, MS, presented on the health effects and mitigation of pollutant exposures at or near schools.
-
Sarcoidosis experts review decisions from diagnosis to transplant
Hakim Azfar Ali, MD, MPH, FCCP, discussed indications and timing for lung transplantation referral in patients with sarcoidosis.
-
Session addresses complex pulmonary vascular challenges in cirrhosis
Yu Kuang (Julie) Lai, MD, detailed the diagnosis of hepatopulmonary syndrome and post-liver transplant hypoxemia during the session, which also reviewed portopulmonary hypertension.
-
Radiologists, pulmonologists to discuss identification of interstitial lung abnormalities
Joe Mammarappallil, MD, PhD, will chair a Monday afternoon session on the recognition and risk stratification of ILAs, including how to differentiate imaging red herrings from findings that point toward progressive fibrosis.
-
90th anniversary sessions to reflect on past, present, and future of field
Nichole T. Tanner, MD, MSCR, FCCP, and five other CHEST experts will chair special sessions about 90 years of progress in mechanical ventilation, TB, lung cancer, diffuse lung disease, respiratory vaccines, and asthma.
-
Panel to outline growing impact of climate change in critical care
Stephanie Maximous, MD, MS, will chair a Sunday morning session on climate change’s growing encroachments in critical illness and acute conditions such as heart attacks, strokes, and asthma exacerbations.
-
Speakers to discuss crucial distinctions of familial, sporadic ILDs
Mary Beth Scholand, MD, FCCP, will serve as co-chair of a Sunday afternoon session on current practices in assessing familial and sporadic ILD patients with telomere measurements and genetic testing.
